Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $13.39 Average Price Target from Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have been assigned an average recommendation of "Buy" from the eight ratings firms that are covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $13.39.

A number of brokerages recently issued reports on VYGR. Cantor Fitzgerald reissued an "overweight" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Wells Fargo & Company set a $10.00 target price on Voyager Therapeutics and gave the company an "overweight" rating in a report on Wednesday, March 12th. Wedbush restated an "outperform" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Voyager Therapeutics in a report on Tuesday, April 8th. Finally, Canaccord Genuity Group lowered their target price on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, March 13th.

Voyager Therapeutics Price Performance

Shares of NASDAQ:VYGR traded up $0.08 during midday trading on Friday, reaching $3.28. 303,242 shares of the company's stock were exchanged, compared to its average volume of 481,437. The firm's 50 day simple moving average is $3.22 and its two-hundred day simple moving average is $4.04. The stock has a market cap of $181.52 million, a price-to-earnings ratio of -2.25 and a beta of 0.85. Voyager Therapeutics has a fifty-two week low of $2.65 and a fifty-two week high of $9.55.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.18). The business had revenue of $6.47 million for the quarter, compared to analyst estimates of $13.55 million. Voyager Therapeutics had a negative return on equity of 27.36% and a negative net margin of 126.49%. Equities research analysts predict that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Voyager Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Strs Ohio purchased a new position in shares of Voyager Therapeutics in the 1st quarter valued at about $256,000. Acadian Asset Management LLC boosted its stake in shares of Voyager Therapeutics by 863.3% in the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company's stock valued at $778,000 after buying an additional 206,758 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of Voyager Therapeutics in the 1st quarter valued at about $218,000. AQR Capital Management LLC boosted its stake in shares of Voyager Therapeutics by 179.3% in the 1st quarter. AQR Capital Management LLC now owns 495,260 shares of the company's stock valued at $1,674,000 after buying an additional 317,927 shares during the period. Finally, Vestal Point Capital LP boosted its stake in shares of Voyager Therapeutics by 1.6% in the 1st quarter. Vestal Point Capital LP now owns 1,249,418 shares of the company's stock valued at $4,223,000 after buying an additional 19,418 shares during the period. Hedge funds and other institutional investors own 48.03% of the company's stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.